Sanofi has entered an agreement to acquire Vigil Neuroscience for approximately $470 million, adding a new investigational ...

Sanofi (NASDAQ:SNY) said Wednesday it agreed to acquire clinical-stage biotechnology company Vigil Neuroscience (NASDAQ:VIGL) ...

Vigil Neuroscience (VIGL) and Sanofi (SNY) announced that it has entered into a definitive merger agreement pursuant to which ...

Vigil’s shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a ...

Sanofi’s 11 months watching over Vigil Neuroscience have led to a $470 million buyout. | Sanofi’s 11 months watching over ...

Sanofi has announced that it will be acquiring Vigil Neuroscience and its investigational Alzheimer’s disease (AD) drug for ...

Hudson has previously said he was looking for M&A deals this year to shore up its already-strong position in immunology, ...

Vigil to be acquired by Sanofi for $10.00 per share, enhancing Alzheimer's treatment development. Expected closure in Q3 2025. Vigil Neuroscience, Inc. has announced a definitive merger agreement ...

France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for over $9 billion to boost its position in ...

From my colleague Adam Feuerstein: French drug maker Sanofi is acquiring the small biotech Vigil Neuroscience for $470 ...

French pharmaceutical giant Sanofi is set to acquire U.S.-based Blueprint Medicines Corporation in a deal worth up to $9.5 ...

PARIS (Reuters) -France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost ...